ArticleHemaSphere2023

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients.

Enrique M Ocio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.